Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Earnings Highlights: New Products Win The Day For Top Pharma

This article was originally published in PharmAsia News

Executive Summary

PharmAsia News brings highlights from Japan’s week of earnings presentations.

You may also be interested in...

Medivation/Astellas Confident Xtandi Data Will PREVAIL With Urologists

The companies expect the demonstrated improvement in progression-free survival will be particularly compelling for urologists treating castrate-resistant prostate cancer in patients who have not started chemotherapy.

Invokana Development Directed By Mechanism Of Action

J&J’s canagliflozin is the first approval for a new pharmacologic approach to diabetes treatment, so FDA and the sponsor looked closely at the mechanism of action to identify safety questions – and to structure a clinical program that would provide data to answer them in the first review cycle.

Obesity Drugs Covered By One-Third Of Large Employers In Survey

The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts